VasoDynamics completes MHRA advisory meeting for NG11-2 clinical development

Phase Ib design and study objectives agreed

21st September 2021 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side effects induced by anti-cancer treatments, today announces that it has successfully completed an MHRA Scientific Advisory Meeting. This clarifies the clinical NG11-2 development path, the company’s innovative oral, topical programme for the prevention of severe radiation-induced oral mucositis (RIOM). During the meeting, the potential for accelerated marketing authorisation was also discussed.

Ningfeng Fiona Li, CEO of VasoDynamics, said:

“Our positive engagement with the MHRA represents a key milestone in the development of our NG11 oral topical platform. We are excited about the potential of NG11-2 to improve the standard of cancer-supportive care for patients worldwide.”

For enquiries, please contact:

Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk

Notes to Editors:

About VasoDynamics

VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve the most effective protection of normal tissue during cancer treatment whilst enhancing anti-cancer therapy efficacy.